1 王刚,姜博文,杨林花,等. 重组人凝血因子Ⅸ小基因及其无义突变体稳定细胞株的构建及意义[J]. 中国实验血液学杂志,2013,21(02):422-425. 2 Kelly M E,Zhuo J,Bharadwaj A S,et al. Induction of immune tolerance to FⅨ following muscular AAV gene transfer is AAV-dose/FⅨ-level dependent[J]. Mol Ther,2009,17(5):857-863. 3 Shapiro A D,Ragni M V,Valentino L A,et al. Recombinant factor IX-Fc fusion protein (rFIXFc) demonstrates safety and prolonged activity in a phase 1/2a study in hemophilia B patients[J]. Blood. 2012, 119(3):666-672. 4 Wang L,Calcedo R,Wang H,et al. The pleiotropic effects of natural AAV infections on liver-directed gene transfer in macaques[J]. Mol Ther. 2010,18(1):126-134. 5 王朝荣. 乙型血友病患者的治疗进展[J]. 国际输血及血液学杂志,2013,36(2):147-150 6 Clifton J,Huang F,Gaso-Sokac D,et al. Use of proteomics for validation of the isolation process of clotting factor Ⅸ from human plasma[J]. J Proteomics,2010,73(3):678-688. 7 Safari S,Zomorodipour A,Amirmozaffari N,et al. Use of a Bacterially Expressed H µMan Factor IX LightChain to Develop Polyclonal Antibody Anti-hFIX[J]. Appl Biochem Biotechnol,2009,159(2):404-414. 8 Brunetti-Pierri N,Grove N C,Zuo Y,et al. Bioengineered Factor IX Molecules with Increased Catalytic Activity Improve the Therapeutic Indexof Gene Therapy Vectors for Hemophilia B[J]. Hum Gene Ther,2009,20(5):479-485. 9 戴永刚,尹胜菊,程凤凤,等. 人凝血因子Ⅸ-V107A-R338A高活性突变体在毕赤酵母中的表达及活性测定[J]. 中国输血杂志,2017,30(3):276-278. |